Hoth Therapeutics Interest Expense 2011-2026 | HOTH

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Hoth Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
27.1 K	-153 K	451 K	-59.6 K	104 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
451 K	-153 K	73.9 K

Quarterly Interest Expense Hoth Therapeutics

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	786	-	-	-	-592	-262	41.7 K	-	-29.1 K	-19.5 K	-12 K	-	49.9 K	18.3 K	-10.1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
49.9 K	-29.1 K	3.91 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Amarin Corporation plc AMRN	7 K	$ 14.67	-0.07 %	$ 6.09 B	Irlanda
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Cabaletta Bio CABA	2 M	$ 2.82	1.44 %	$ 283 M	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.29	-3.01 %	$ 329 M	Britain
CEL-SCI Corporation CVM	746 K	$ 3.47	-1.7 %	$ 221 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	874 K	$ 1.09	-9.17 %	$ 22.4 M	Israel
Enochian Biosciences ENOB	122 K	-	-	$ 40.5 M	USA
Equillium EQ	-76 K	$ 2.06	-	$ 118 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 2.85	3.26 %	$ 592 M	USA
Eton Pharmaceuticals ETON	955 K	$ 23.45	-1.64 %	$ 631 M	USA
China SXT Pharmaceuticals SXTC	1.62 M	$ 1.32	-5.2 %	$ 1.88 M	China
CRISPR Therapeutics AG CRSP	86.6 M	$ 47.55	0.98 %	$ 4.28 B	Schweiz
Arbutus Biopharma Corporation ABUS	459 K	$ 4.45	-1.77 %	$ 853 M	Canada
Allakos ALLK	8 K	-	-	$ 28.6 M	USA